Safety of Ticagrelor plus Warfarin versus Traditional Triple Antithrombotic Therpay Regimen in Patients with Persistent or Permanent Atrial Fibrillation and undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial

Trial Profile

Safety of Ticagrelor plus Warfarin versus Traditional Triple Antithrombotic Therpay Regimen in Patients with Persistent or Permanent Atrial Fibrillation and undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 May 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel; Warfarin
  • Indications Atrial fibrillation; Coronary artery disease; Haemorrhage
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
    • 15 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Feb 2018.
    • 05 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top